The molecular classification of multiple myeloma.
暂无分享,去创建一个
John Crowley | Simona Colla | Bart Barlogie | James P Stewart | Yongsheng Huang | Yongsheng Huang | J. Stewart | F. Zhan | I. Hanamura | B. Barlogie | J. Shaughnessy | E. Anaissie | G. Tricot | R. Walker | S. Colla | M. Zangari | J. Sawyer | J. Epstein | F. van Rhee | B. Burington | K. Hollmig | M. Pineda‐Roman | J. Crowley | S. Yaccoby | Frits van Rhee | Sushil K. Gupta | Fenghuang Zhan | Ichiro Hanamura | Sushil Gupta | Joshua Epstein | Shmuel Yaccoby | Jeffrey Sawyer | Bart Burington | Elias Anaissie | Klaus Hollmig | Mauricio Pineda-Roman | Guido Tricot | Ronald Walker | Maurizio Zangari | John D Shaughnessy | J. Stewart
[1] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[2] P. L. Bergsagel,et al. Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.
[3] M. Callanan,et al. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B‐cell lymphoma and multiple myeloma , 2001, Genes, chromosomes & cancer.
[4] F. Magrangeas,et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma , 2005, Leukemia.
[5] M. Baccarani,et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. , 2003, Blood.
[6] J. Soulier,et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases , 2003, Genes, chromosomes & cancer.
[7] G. Ahmann,et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.
[8] J. Crowley,et al. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience , 2003, British journal of haematology.
[9] R. Bataille,et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. , 2003, Blood.
[10] John Crowley,et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.
[11] L. Staudt,et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. , 2004, Cancer cell.
[12] H. Goldschmidt,et al. High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis , 2003, Leukemia.
[13] Gonzalez,et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.
[14] J. Shaughnessy,et al. Role of osteoblast suppression in multiple myeloma , 2006, Journal of cellular biochemistry.
[15] S. Ely,et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. , 2005, Cancer research.
[16] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] H. Kaufmann,et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. , 2000, Blood.
[18] R. Tibshirani,et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.
[19] U. Jäger,et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma , 2004, Leukemia.
[20] D. Harrington,et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. , 2002, Cancer research.
[21] Bart Barlogie,et al. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling , 2003, Immunological reviews.
[22] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[23] A I Pick,et al. THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.
[24] L. Staudt,et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.
[25] F. Zhan,et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma , 2005, Oncogene.
[26] J. D. Vos,et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.
[27] B. Barlogie,et al. Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants , 2002, British journal of haematology.
[28] Marie Joseph,et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[30] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] J. Chirgwin,et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] Bart Barlogie,et al. Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.
[33] K. Tarte,et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. , 2003, Blood.
[34] G D Roodman,et al. Biology of osteoclast activation in cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[36] F. Zhan,et al. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. , 2003, Blood.
[37] Terry M Therneau,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.
[38] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[39] G. Ahmann,et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. , 2005, Blood.
[40] J. Esteve,et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma , 2005, British journal of haematology.
[41] B. Barlogie. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. , 2003, Seminars in hematology.
[42] F. Zhan,et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. , 2003, Blood.
[43] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[44] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.
[45] K. Anderson,et al. Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays , 2002, Oncogene.
[46] F. Zhan,et al. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray , 2004, Modern Pathology.
[47] E. Montserrat,et al. Long-term survival in multiple myeloma. , 1986, Archives of internal medicine.
[48] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] L. Chin,et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. , 2006, Cancer cell.
[50] B. Barlogie,et al. Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q , 2005, Genes, chromosomes & cancer.
[51] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[52] D. Hose,et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics , 2005, Genes, chromosomes & cancer.
[53] F. Magrangeas,et al. Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma. , 2004 .
[54] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[55] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[56] G. Ahmann,et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.
[57] Tony Reiman,et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.
[58] Yongsheng Huang,et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.
[59] J. Downing,et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.
[60] F. Zhan,et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. , 2003, Blood.
[61] M. Pallavicini,et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization , 1997, Genes, chromosomes & cancer.
[62] L. Hofbauer,et al. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. , 2005, Biochemical and biophysical research communications.
[63] C. Bastard,et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.
[64] J. Hernández,et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. , 2004, Blood.
[65] B. Barlogie,et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. , 1998, Blood.
[66] R. Bataille,et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. , 2003, Blood.
[67] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[68] R S Chaganti,et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. , 1998, Blood.
[69] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[70] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[71] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.